Antibacterial Effect of Silver Nanoparticles on Multi Drug Resistant Pseudomonas Aeruginosa
Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 32870
Antibacterial Effect of Silver Nanoparticles on Multi Drug Resistant Pseudomonas Aeruginosa

Authors: Athirah Nur Amirulhusni, Navindra Kumari Palanisamy, Zaini Mohd-Zain, Liew Jian Ping, R.Durairaj


Multidrug resistant organisms have been taunting the medical world for the last few decades. Even with new antibiotics developed, resistant strains have emerged soon after. With the advancement of nanotechnology, we investigated colloidal silver nanoparticles for its antimicrobial activity against Pseudomonas aeruginosa. This organism is a multidrug resistant which contributes to the high morbidity and mortality in immunocompromised patients. Five multidrug resistant strains were used in this study. The antimicrobial effect was studied using the disc diffusion and broth dilution techniques. An inhibition zone of 11 mm was observed with 10 μg dose of the nanoparticles. The nanoparticles exhibited MIC of 50 μg/ml when added at the lag phase and the subinhibitory concentration was measured as 100 μg/ml. The MIC50 value showed to be 15 μg/ml. This study suggests that silver nanoparticles can be further developed as an antimicrobial agent, hence decreasing the burden of the multidrug resistance phenomena.

Keywords: Antimirobial activity, Multidrug resistance, Pseudomonas aeruginosa, Silver nanoparticles

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 5390


[1] Goossens, H. (2003). "Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study groupÔÇá." Clinical Microbiology and Infection 9(9): 980-983.
[2] Kerr, K. G. and A. M. Snelling (2009). "Pseudomonas aeruginosa: a formidable and ever-present adversary." Journal of Hospital Infection 73(4): 338-344.
[3] Foran, S. M. (2009). Therapeutic Properties of Silver : An Historical and Technical Review. Quanta.
[4] Mudshinge, S. R., A. B. Deore, et al. (2011). "Nanoparticles: Emerging carriers for drug delivery." Saudi Pharmaceutical Journal 19(3): 129- 141.
[5] Kim, J. S., E. Kuk, et al. (2007). "Antimicrobial effects of silver nanoparticles." Nanomedicine: Nanotechnology, Biology and Medicine 3(1): 95-101.
[6] Bhupendra Chudasama, A. K. V., Nidhi Andhariya, R. V. Metha, R. V. Upadhyay (2010). "Highly bacterial resistant silver nanoparticles : synthesis and antibacterial activities."
[7] Shahverdi, A. R., A. Fakhimi, et al. (2007). "Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli." Nanomedicine: Nanotechnology, Biology and Medicine 3(2): 168-171.
[8] Clinical and Laboratory Standards Institute (2000): Performance standards for antimicrobial susceptibility testing (Wayne, P.A) 1995: 15th informational supplement. Document M100- S15.
[9] Ivan Sondi, B. S.-S. (2004). "Silver nanoparticles as antimicrobial agent : a case study on E. coli as a model for Gram-negative bacteria." Journal of Colloid and Interface Science: 177 - 182.
[10] Lisa A. Spacek, M. D., Ph.D.; Khalil G. Ghanem, M.D. (2011). Pseudomonas aeruginosa, Unbound Medicine.
[11] Yamanaka, M., K. Hara, et al. (2005). "Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis." Applied and environmental microbiology 71(11): 7589.
[12] Batarseh, K. I. (2004). "Anomaly and correlation of killing in the therapeutic properties of silver (I) chelation with glutamic and tartaric acids." Journal of Antimicrobial Chemotherapy 54(2): 546-548.